The largest community of pharma leaders

Michael J. Reilly Promoted to CEO of Integrity Bio

THOUSAND OAKS, Calif.–()–Integrity Bio has announced the promotion of Michael Reilly as their new Chief Executive Officer. Founder, owner and previous CEO, Byeong Chang, will continue as Chief Scientific Officer.

Founded in 2003, Integrity Bio’s mission is to provide help to those who strive to save or improve the quality of human life by providing them the integrated services of Formulation Development, GMP Fill Finish Services, and Innovative Drug Delivery technologies.

“Byeong has been an inspirational leader for all of us, and after nearly two decades at the helm of Integrity Bio has now been thinking ahead about how to position the company for the future,” said Mr. Reilly. “It’s been a real privilege for me to work with Integrity Bio over the last eight years, and I’m excited to take the helm now as we have some big things planned for the coming year and beyond. I share Byeong’s optimism for the firm’s bright future in this growing field.”

“The timing is right to hand over the reins,” commented Byeong Chang. “Having worked very closely together, I have tremendous trust and confidence in Michael and believe he is the right person to lead this next phase of our growth.”

During his time at Integrity Bio, Mr. Reilly has served as VP of Business Development and led the company’s Excelse Bio high-concentration formulation technology division. Prior to that, he held senior positions at Baxter BioScience and Amgen.

Integrity Bio specializes in biologics formulation development and drug product manufacturing and has formulated over 200 biologics including vaccines, antibodies, proteins, and peptides for more than 150 firms. The company has expertise in hard-to-formulate products in liquid and lyophilized forms.

Integrity Bio is located in Camarillo and Thousand Oaks, California, the center of a highly concentrated cluster of over 5,000 biotech professionals. Demand for their research services increased by 30% in the past year, driving continued expansion.

If you would like more information, contact Brendon Keiser at 805-445-8422 x154 or brendon.keiser@integritybio.com

Source

0FansLike
0FollowersFollow
0FollowersFollow
0FollowersFollow

Recent Articles

bioAffinity Technologies Announces Dr. Martin Tammemägi to Chair Scientific and Medical Advisory Board

SAN ANTONIO--(BUSINESS WIRE)-- #CyPathLung--bioAffinity Technologies, a privately held biotech company, today...

Evaluate Ltd. Launches Evaluate Omnium, Transforming Pharma’s Approach to Quantifying the Risk and Return of Novel Drugs

LONDON & BOSTON & TOKYO--(BUSINESS WIRE)-- #biopharma--Evaluate Ltd., the leading provider...

HCPLive® and the American Lung Association Unveil Exclusive Interview with Anthony S. Fauci, M.D.

CRANBURY, N.J.--(BUSINESS WIRE)-- #AnthonyFauci--Dr. Anthony Fauci joined Lungcast, the @MDMagazine and...

MedinCell Initiates the First Clinical Trial of Its Covid-19 Prevention Program

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access the complete press release About MedinCell...

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

SUZHOU, China--(BUSINESS WIRE)--CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co....
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.